Acelyrin, INC Form 4 insider transactions

AyurMaya Capital Management Company, LP and David E. Goel have reported the disposition of over 9.3 million shares of ACELYRIN, Inc. common stock, valued at $0, as a result of the company's merger with Alumis Inc., where each share was converted into 0.4274 shares of Alumis common stock.

ACELYRIN, Inc. Chief Executive Officer Mina Kim's beneficial ownership in the company has been fully converted into Alumis, Inc. equity following the completion of the merger on May 21, 2025.

A recent SEC Form 4 filing reveals the conversion of Director Bruce C. Cozadd's stock options in ACELYRIN, Inc. into Alumis, Inc. shares following the successful merger of the two companies.

ACELYRIN's Chief Legal Officer, Amar Murugan, has reported the conversion of his common stock, restricted stock units, and stock options into Alumis, Inc. securities following the merger of ACELYRIN into Alumis.

ACELYRIN, Inc. Director Beth Seidenberg has reported the disposition of all her direct and indirect holdings of common stock and stock options in ACELYRIN, Inc. as a result of the company's merger with Alumis, Inc. on May 21, 2025.

ACELYRIN, Inc.'s Chief Medical Officer, Shephard Mpofu, has reported the conversion of all his common stock and employee stock options into securities of Alumis, Inc. following the completion of their merger.

A recent SEC Form 4 filing reveals that ACELYRIN, Inc. Director Henry O. Gosebruch's common stock and stock options were converted into Alumis, Inc. shares and options following the completion of the merger on May 21, 2025.

A recent SEC Form 4 filing reveals that ACELYRIN, Inc. Director Patrick Machado's common stock and stock options were converted into Alumis, Inc. shares and options following the completion of the merger between the two companies.

Dawn Svoronos, a Director of ACELYRIN, Inc., has reported the disposition of all her common stock and stock options in ACELYRIN following the company's merger with Alumis, Inc. on May 21, 2025.

A recent SEC Form 4 filing reveals that Daniel J. Becker, a director at ACELYRIN, Inc., has converted all his common stock and stock options into shares of Alumis, Inc. common stock as a result of ACELYRIN's merger into a wholly-owned subsidiary of Alumis on May 21, 2025.

A recent SEC Form 4 filing reveals that ACELYRIN, Inc. Director Lynn A. Tetrault's equity and stock options in ACELYRIN have been converted into shares and options of Alumis, Inc. following the merger of the two companies.

CEO Mina Kim reports vesting of performance-based restricted stock units and subsequent tax withholding of shares.

Leading proxy advisory firm ISS recommends ACELYRIN stockholders vote in favor of the proposed merger with Alumis, citing potential upside and strategic rationale.

ACELYRIN reiterates its confidence that the proposed combination with Alumis is the best path forward and the most value-maximizing outcome for all ACELYRIN stockholders, urging them to vote in favor at the upcoming special meeting.

Alumis Inc. and ACELYRIN, Inc. have announced a definitive agreement for an all-stock merger, aiming to create a well-capitalized biopharmaceutical company focused on immune-mediated diseases with a cash runway into 2027.

Alumis and ACELYRIN have amended their merger agreement, granting ACELYRIN stockholders approximately 48% ownership in the combined company following the merger's completion.

Alumis and ACELYRIN have amended their merger agreement, adjusting the stock exchange ratio to reflect current market conditions and investor expectations.

ACELYRIN and Alumis have amended their merger agreement, increasing ACELYRIN stockholders' ownership in the combined company to approximately 48% on a fully diluted basis.

Alumis and ACELYRIN have amended their merger agreement, increasing the ownership stake for ACELYRIN stockholders in the combined company to approximately 48% on a fully diluted basis.

Alumis and ACELYRIN have jointly filed a definitive proxy statement/prospectus regarding their proposed merger, with stockholders set to vote on the transaction at special meetings in May 2025.

Alumis and Kaken Pharmaceutical Co., Ltd. have entered into a collaboration and license agreement for ESK-001 in Japan, securing a key market and extending Alumis' cash runway.

Acelyrin's CEO, Mina Kim, sold 17,986 shares of common stock on March 17, 2025, to cover tax obligations related to the vesting and settlement of restricted stock units.

Amar Murugan, Chief Legal Officer of Acelyrin, Inc., sold 3,913 shares of common stock on March 17, 2025, to cover tax obligations related to vesting and settlement of restricted stock units.

Shephard Mpofu, Chief Medical Officer of Acelyrin, Inc., sold 3,211 shares of common stock on March 17, 2025, to cover tax obligations related to vested restricted stock units.

Alumis Inc. announces a merger agreement with ACELYRIN, along with its year-end 2024 financial results and clinical development updates.

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement to create a leading clinical biopharmaceutical company focused on immune-mediated diseases.

ACELYRIN, INC. adopts a limited-duration stockholder rights plan in response to Tang Capital Partners' increasing stake in the company.

Alumis and ACELYRIN have announced a merger agreement to create a well-capitalized, late-stage clinical biopharmaceutical company focused on developing and commercializing transformative therapies for immune-mediated diseases.

ACELYRIN and Alumis have agreed to an all-stock merger, creating a late-stage clinical biopharmaceutical company focused on immune-mediated diseases with a combined cash runway extending into 2027.

Alumis Inc. and ACELYRIN, Inc. have announced a definitive agreement for an all-stock merger, aiming to create a well-capitalized, late-stage clinical biopharmaceutical company focused on immune-mediated diseases.